Navigation Links
Sinovac Reports Unaudited First Quarter 2010 Financial Results
Date:5/13/2010

407 5,386,749 Deferred research grants 1,360,908 1,331,476 Deferred tax liability 1,835,953 1,398,123 Total current liabilities 41,000,566 50,012,412 Deferred government grants 2,581,188 2,646,669 Loans payable 8,264,946 -- Long term payable 407,847 407,794 Deferred revenue 6,943,738 6,942,824 Total long term liabilities 18,197,719 9,997,287 Total liabilities 59,198,285 60,009,699 Commitments and contingencies EQUITY Preferred stock -- -- Authorized 50,000,000 shares at par value of $0.001 each Issued and outstanding: nil Common stock 54,097 42,585 Authorized: 100,000,000 shares at par value of $0.001 each Issued and outstanding: 54,097,261 (2009- 42,585,261 ) Additional paid in capital 104,493,734 42,533,876 Accumulated other comprehensive income 4,232,442 4,225,196 Dedicated reserves 9,863,251 9,863,251 Retained earnings 13,685,977 13,993,287 Total stockholders' equity 132,329,501 70,658,195 Non-controlling interests 33,383,849 13,808,247 Total equity 165,713,350 84,466,442 Total liabilities and equity $224,911,635 $144,476,141 SINOVAC BIOTECH LTD. Incorporated in Antigua and Barbuda Consolidated Statements of Income (Loss) and Comprehensive Income (Loss) Three Months Ended March 31, 2010
'/>"/>
SOURCE Sinovac Biotech Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Sinovac to Host Conference Call to Report First Quarter 2010 Financial Results
2. Sinovac Announces Upsizing and Pricing of Common Share Offering
3. Sinovac Files Clinical Trial Application with SFDA for Vaccine Against Hand, Foot, and Mouth Disease
4. Sinovacs CEO Weidong Yin Presented with Annual Innovation Award by China Central Television
5. Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities
6. Sinovac Reports Unaudited Third Quarter 2009 Financial Results
7. Sinovac Obtains Third H1N1 Vaccine Order from Chinese Central Government
8. Sinovac Receives Certificate of Approval to Distribute Panflu (H5N1) Vaccine in Hong Kong
9. Sinovac to Present at 2009 UBS Global Life Sciences Conference
10. Sinovac Obtains Lot Release Certificate for Its First Batch of H1N1 Vaccine
11. Sinovac Obtains Initial Order of H1N1 Vaccine from Chinese Central Government
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... ... 26, 2015 , ... MediVet Biologics, a leader in Veterinary ... to open in Manhattan, Kansas in early October, 2015. The location of the ... and development through collaboration with researchers from Kansas State University’s College of Veterinary ...
(Date:8/26/2015)...  Platform therapeutic company Symic Biomedical, Inc. ("Symic") ... Phase II SBIR grant from the National Institutes ... agent to reduce arteriovenous fistula (AVF) failures, a ... disease (ESRD) patients undergoing hemodialysis. The two-year project, ... Digestive and Kidney Diseases (NIDDK), will allow Symic ...
(Date:8/26/2015)... 26, 2015 Despite recent ... the optimism in biotech,s forecast is the recent ... sciences advancements.  Active biotechnology & healthcare companies with ... (OTCQB: PBIO), Sequenom, Inc. (NASDAQ: SQNM ), ... Pharmaceutical Corp. (NASDAQ: RPTP ) and EnteroMedics ...
(Date:8/25/2015)... ... August 25, 2015 , ... Vets Plus, Inc. ... Wis. The company has added a AS16 Sharples centrifuge to harvest products after ... bacterial or fungal fermentation process development. , The new centrifuge greatly expands ...
Breaking Biology Technology:MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 3Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 2New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 3New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 4New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 5New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 6New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 7New centrifuge and fermentor expand product development capacity at Vets Plus 2
... , OLDSMAR, Fla., Oct. 6 Cryo-Cell International, a ... be making progress in the fight against breast cancer ... blood. In honor of National Breast Cancer Awareness ... Cure® through C,elle®, the company,s service which enables women ...
... ... delivering novel nanotechnology solutions for instantly assessing the metabolic health of the nearly ... medical infrastructure. , ... Santa Barbara, CA (PRWEB) October 6, 2009 -- NanoStar™ Health Corporation ...
... /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex:YMI, TSX:YM, ... identifies and advances a diverse portfolio of promising ... announced it has proposed to merge Cytopia Ltd., ... Cytopia,s lead products are CYT997, a novel vascular ...
Cached Biology Technology:Cryo-Cell International's Stem Cell Research and Development Helps the Fight Against Breast Cancer 2Cryo-Cell International's Stem Cell Research and Development Helps the Fight Against Breast Cancer 3Nanomedicine Company Focuses on Improving Premature Infant Health and Reducing Death Rate 2Nanomedicine Company Focuses on Improving Premature Infant Health and Reducing Death Rate 3Nanomedicine Company Focuses on Improving Premature Infant Health and Reducing Death Rate 4YM BIOSCIENCES ANNOUNCES OFFER FOR CYTOPIA LTD., AN AUSTRALIAN CANCER-FOCUSED DEVELOPMENT COMPANY 2YM BIOSCIENCES ANNOUNCES OFFER FOR CYTOPIA LTD., AN AUSTRALIAN CANCER-FOCUSED DEVELOPMENT COMPANY 3YM BIOSCIENCES ANNOUNCES OFFER FOR CYTOPIA LTD., AN AUSTRALIAN CANCER-FOCUSED DEVELOPMENT COMPANY 4YM BIOSCIENCES ANNOUNCES OFFER FOR CYTOPIA LTD., AN AUSTRALIAN CANCER-FOCUSED DEVELOPMENT COMPANY 5YM BIOSCIENCES ANNOUNCES OFFER FOR CYTOPIA LTD., AN AUSTRALIAN CANCER-FOCUSED DEVELOPMENT COMPANY 6
(Date:8/18/2015)... , Aug. 18, 2015  Navitas ... key contributor to the Submission Content Management ... IRISS, a non-profit forum. Dedicated to the Implementation ... a neutral platform for industry, vendors, health ... information and work towards a standard method ...
(Date:8/12/2015)... 2015 As the digital payment ... and advanced biometrics technology is accelerating beyond expectations.  While ... on using their credit cards, the digital currency, mobile ... payment services led by companies in the space such ... Inc. (NASDAQ: GOOG ), Apple Inc. (NASDAQ: ...
(Date:8/10/2015)... Germany , August 10, 2015 /PRNewswire/ ... world leader in Eye Tracking Technology for more than ... Eye Tracking Platform for integration into all consumer display ... designs for seamless integration of eye tracking into consumer ... and augmented reality smart glasses. Omnivision,s leading sensor technology ...
Breaking Biology News(10 mins):Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3
... from Kent State University and the University of ... species Cycloprosopon dobrogea in eastern Romania. Previously unexamined, ... more than 150 million years ago during the ... crabs helps determine various aspects of biodiversity and ...
... St. Paul, Minn. (October 17, 2007) Deadlines ... reservations are quickly approaching for the 2007 National ... Symposium will be held December 12-14, 2007 at ... The 2007 symposium, organized by The American ...
... imagist and researcher at Harvard University,s Initiative in ... the 2007 Lennart Nilsson Award. Frankel was sited ... art and crystal-clear scientific illustrations both fascinating ... community alike. The Lennart Nilsson Award is ...
Cached Biology News:Deadlines for 2007 National Soybean Rust Symposium fast approaching 2Lennart Nilsson Award 2007 2